Acurx Pharmaceuticals Inc (ACXP)       3.79  +0.16 (+4.41%)

3.79  +0.16 (+4.41%)

US00510M1045 - Common Stock

Acurx Pharmaceuticals Inc3.79

NASDAQ:ACXP (6/30/2022, 7:00:00 PM)+0.16 (+4.41%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 05-10 2022-05-10/amc Earnings (Next) N/A N/A
Ins Owners 22.72% Inst Owners 3.1%
Market Cap 38.90M Shares 10.26M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82.86
IPO 06-25 2021-06-25

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACXP Daily chart

Company Profile

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Staten Island, New York and currently employs 3 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in developing a class of antibiotics for infections caused by bacteria listed as pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the United States Food and Drug Administration (FDA). The firm develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. Its research and development pipeline include clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus, including vancomycin-resistant strains (VRE), Staphylococcus, including methicillin-resistant strains (MRSA) and Streptococcus, including antibiotic resistant strains.

Company Info

Acurx Pharmaceuticals Inc

259 Liberty Avenue

Staten Island NEW YORK

P: 19175331469.0

CEO: David P. Luci

Employees: 3

Website: https://www.acurxpharma.com/

ACXP Twits

Here you can normally see the latest stock twits on ACXP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example